SRPT Sarepta Therapeutics Options Ahead of EarningsAnalyzing the options chain and the chart patterns of SRPT Sarepta Therapeuticsprior to the earnings report this week,
I would consider purchasing the 120usd strike price Calls with
an expiration date of 2025-8-15,
for a premium of approximately $9.30.
If these options prove to be profitable prior t
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.231 CHF
213.64 M CHF
1.73 B CHF
91.14 M
About Sarepta Therapeutics, Inc.
Sector
Industry
CEO
Douglas S. Ingram
Website
Headquarters
Cambridge
Founded
1980
FIGI
BBG00LVGD035
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here:
Then you need to know that there is a Massive catalyst coming!
Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November.
This week institutions bought calls worth more than $10Mil that SRPT
SRPT strong supportSRPT is at a very strong support at the moment and entries can be made now if fundamentals of the company are strong
Entry @ CMP or 107 to 100
SL @ 97
TP 1 @ 120
TP 2 @ 132
This is when we are expecting that it will bounce back up from the strong support of 105
104-106 range (Strong Suppor
SRPT (Sarepta) is Bull to at least 72.81Prediction: SRPT (Sarepta) is Bull to at least 72.81
Reasons:
A good/decent Bull Pattern has emerged (Before closing) that is pointing upwards, and the Trends momentum is strong enough to push through the current resistance and reach the next resistance point of 72.81. And also, the main index for
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
SRPT5657414
Sarepta Therapeutics, Inc. 1.25% 15-SEP-2027Yield to maturity
4.72%
Maturity date
Sep 15, 2027
See all AB3A bonds
Curated watchlists where AB3A is featured.
Related stocks
Frequently Asked Questions
The current price of AB3A is 69.459 CHF — it has decreased by −27.28% in the past 24 hours. Watch SAREPTA THERA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange SAREPTA THERA INC stocks are traded under the ticker AB3A.
We've gathered analysts' opinions on SAREPTA THERA INC future price: according to them, AB3A price has a max estimate of 171.73 CHF and a min estimate of 57.52 CHF. Watch AB3A chart and read a more detailed SAREPTA THERA INC stock forecast: see what analysts think of SAREPTA THERA INC and suggest that you do with its stocks.
AB3A reached its all-time high on Jun 24, 2024 with the price of 145.362 CHF, and its all-time low was 67.382 CHF and was reached on Nov 1, 2023. View more price dynamics on AB3A chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AB3A stock is 37.51% volatile and has beta coefficient of 1.22. Track SAREPTA THERA INC stock price on the chart and check out the list of the most volatile stocks — is SAREPTA THERA INC there?
Today SAREPTA THERA INC has the market capitalization of 4.29 B, it has increased by 0.38% over the last week.
Yes, you can track SAREPTA THERA INC financials in yearly and quarterly reports right on TradingView.
SAREPTA THERA INC is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
AB3A earnings for the last quarter are 1.36 CHF per share, whereas the estimation was 1.71 CHF resulting in a −20.32% surprise. The estimated earnings for the next quarter are −2.78 CHF per share. See more details about SAREPTA THERA INC earnings.
SAREPTA THERA INC revenue for the last quarter amounts to 597.97 M CHF, despite the estimated figure of 569.97 M CHF. In the next quarter, revenue is expected to reach 608.58 M CHF.
AB3A net income for the last quarter is 144.45 M CHF, while the quarter before that showed 28.48 M CHF of net income which accounts for 407.14% change. Track more SAREPTA THERA INC financial stats to get the full picture.
No, AB3A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 19, 2025, the company has 1.37 K employees. See our rating of the largest employees — is SAREPTA THERA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SAREPTA THERA INC EBITDA is 247.00 M CHF, and current EBITDA margin is 14.30%. See more stats in SAREPTA THERA INC financial statements.
Like other stocks, AB3A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SAREPTA THERA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SAREPTA THERA INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SAREPTA THERA INC stock shows the strong sell signal. See more of SAREPTA THERA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.